VANDA PHARMACEUTICALS INC. (NASDAQ:VNDA) Files An 8-K Other Events

Item 8.01.

On September13, 2017, Vanda Pharmaceuticals Inc. issued a press
release announcing results from an eight-week randomized study of
tradipitant as a monotherapy in the treatment of chronic pruritus
in patients with atopic dermatitis. A copy of the press release
is filed as Exhibit99.1 hereto and incorporated by reference
herein.

Vanda Pharmaceuticals Inc. Exhibit
EX-99.1 2 d362084dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Vanda’s Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis     •   Worst Itch Visual Analog Scale (Worst Itch VAS): Tradipitant vs. Placebo p=0.019     •   Scoring Atopic Dermatitis (SCORAD): Tradipitant vs. Placebo p=0.008 Management to host conference call on Thursday,…
To view the full exhibit click here

About VANDA PHARMACEUTICALS INC. (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. The Company offers HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). The Company offers Fanapt (iloperidone) for the treatment of schizophrenia. Additionally, its distribution partners launched Fanapt in Israel and Mexico. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. It is indicated for the treatment of CNS Disorders.